key: cord-0911182-8rgm4na5
authors: TG Tighe, Nathaniel; McClain, Craig D; Vlassakova, Bistra G; Cravero, Joseph P; Peyton, James M; Kovatsis, Pete G; Park, Raymond S; Stein, Mary Lyn
title: Aerosol Barriers in Pediatric Anesthesiology: clinical data supports FDA caution
date: 2020-11-29
journal: Paediatr Anaesth
DOI: 10.1111/pan.14091
sha: 4f9933b28194ada33150089379e5c774fb6b0f9b
doc_id: 911182
cord_uid: 8rgm4na5

The COVID‐19 pandemic has prompted rapid development and deployment of a variety of unproven physical barriers intended to protect providers from aerosols generated during airway management(1,2). The US Food and Drug Administration (FDA) initially granted an umbrella emergency use authorization (EUA) for passive protective barrier enclosures on May 1, 2020. Although anecdotal evidence drove widespread adoption of these devices, there are no data we are asware of demonstrating they protect providers from infection with the SARS‐CoV‐2 virus. Furthermore, some have expressed concern about their safety and efficacy for both patients and providers(3), with particular concern that barriers may prolong intubation times and increase the risk of hypoxemia(4).

The COVID-19 pandemic has prompted rapid development and deployment of a variety of unproven physical barriers intended to protect providers from aerosols generated during airway management 1,2 . The US Food and Drug Administration (FDA) initially granted an umbrella emergency use authorization (EUA) for passive protective barrier enclosures on May 1, 2020. Although anecdotal evidence drove widespread adoption of these devices, there are no data we are aware of demonstrating they protect providers from infection with the SARS-CoV-2 virus. Furthermore, some have expressed concern about their safety and efficacy for both patients and providers 3 , with particular concern that barriers may prolong intubation times and increase the risk of hypoxemia 4 . We report our initial experience with aerosol barrier devices in pediatric patients and raise concerns that they may increase risk to patients.

In March 2020, our airway group developed and implemented plastic aerosol barrier devices as a component of our perioperative COVID-19 workflow 3 . Simulation sessions using supporting documentation including videos for donning/doffing personal protective equipment, and intubating patients with suspected and confirmed COVID19 were provided to all clinicians starting in mid-March prior to the care of any known COVID19 cases at our institution. Aerosol barriers were used at the discretion of the attending anesthesiologist and clinical team and consisted of plastic sheets draped over the patient with or without a transparent plexiglass shield (Figure 1 ). Barriers provided ample working space around the patient's head to allow unencumbered preoxygenation. As part of our quality improvement process, we obtained detailed feedback via a web-based survey after cases were performed while using these aerosol barriers.

This review of our quality assurance data was deemed exempt by our institutional review board.

As of June 30, 2020, 49 pediatric patients age 1mo-18years with anatomically normal airways and either PCR confirmed or suspected COVID-19 have received anesthesia care at our institution. Of these, 36 were intubated using an aerosol barrier and standard (i.e. Macintosh or Miller) blade video laryngoscopy, 5 were intubated without aerosol barriers, and 8 were maintained with spontaneous respirations and face mask oxygen.

Experienced providers had more difficulty than expected in six (16.7%) of the 36 cases using aerosol barriers (Table 1) .

Four cases required multiple attempts to secure the airway and two cases involved pronounced difficulty in a single attempt. All cases with reported difficulty were managed by experienced anesthesia providers (senior anesthesia trainee, CRNA, or attending anesthesiologist). This difficulty occurred in otherwise healthy (ASA 1 or 2) children age 2-18 years with anatomically normal airways presenting for routine emergency procedures. Subjective feedback solicited from the providers indicated that the aerosol barrier was seen as a contributing factor to the difficulty in all six of these

This article is protected by copyright. All rights reserved cases. The patients in these cases underwent rapid sequence inductions followed by standard (i.e. Macintosh or Miller) blade video laryngoscopy in accordance with published guidelines 5 . The airway was ultimately secured by orotracheal intubation with a reported grade 1 Cormack-Lehane view on video laryngoscopy in all cases. Although difficulty was encountered, none of these patients suffered any apparent complications from airway management.

As part of a separate quality improvement effort, we collected data on the airway management and airway related adverse events for every patient cared for at our institution over a two-week period in May and June 2020. The same clinicians were involved in the care of these patients and the patients with suspected or PCR confirmed COVID19. Per institutional policy during this time period, standard surgical mask, gloves, and eye protection were worn for COVID negative patients, but not N95s or PAPRs. In this audit, we identified 173 patients who were ASA physical status 1 or 2, ages 2 to 18 years, COVID-19 negative, asymptomatic, and did not have a history of difficult intubation who were intubated without the use of an aerosol barrier. 4 of 173 patients (2.3%) required more than one attempt to intubate by an experienced provider. Of these 4 patients, one was designated as an emergency case and none underwent rapid sequence induction. Rapid sequence induction and intubation without an aerosol barrier was performed in 9 ASA 1 and 2 patients age 2-18 years in the COVID negative, asymptomatic group during this two week audit. Clinicians performed direct laryngoscopy for 8patients and standard blade video laryngoscopy in 1 patient. All were successfully intubated on the first attempt, and none experienced adverse events associated with intubation.

Following implementation of plastic aerosol barrier devices into our clinical workflow, we found that experienced providers had difficulty during intubations of patients with anatomically straightforward airways. This finding drove us to share our early quality assurance data with the wider anesthesia community as use of barriers may result in unanticipated difficulties with airway management, particularly in pediatric patients. This difficulty may arise from the visual and physical interference caused by the barrier, which is further exacerbated by the stress associated with caring for potentially infectious patients. Such difficulty could lead to hypoxemia or other patient harm, although no patient in this cohort experienced intubation related adverse events.

The nature of the COVID19 pandemic led to rapid development and implementation of new clinical workflows. We implemented training and simulation prior to their clinical use; still, our preliminary experience revealed important challenges. In response to these observations, we set up a dedicated operating room for Just-in-Time simulation training 6 with the tools and aerosol barriers, which has subjectively improved the comfort of staff using these new techniques. It is notable that five of the cases discussed above occurred prior to instituting the Just-in Time training, and

This article is protected by copyright. All rights reserved only one occurred since that time. We are conducting ongoing monitoring for adverse events through our quality improvement program.

On August 21, 2020, the FDA withdrew the umbrella EUA and advised against the use of protective barrier enclosures without negative pressure due to simulations demonstrating increased exposure to airborne particles to healthcare provider as well as concerns about risk to patients 4, 7 . Our initial experience in pediatric patients is the first such report in patients and is consistent with the simulation data cited in the FDA letter raising concern about potential harm to patients. We have stopped using aerosol barriers in the care of patients with suspected or confirmed COVID19 at our institution. There are important limitations of this observational report of subjective difficulty with intubation based on quality assurance data from a small sample at single institution without a defined research protocol or control group.

Nevertheless, our experience highlights the need for a careful analysis of the risks and benefits of using an aerosol barrier for airway management, and provides clinical data which corroborates the simulation data prompting the FDA to withdraw support of barriers. 

Barrier Enclosure during Endotracheal Intubation

Intubation precautions in a pediatric patient with severe COVID-19

More on Barrier Enclosure during Endotracheal Intubation

The aerosol box for intubation in coronavirus disease 2019 patients: an in-situ simulation crossover study

Pediatric Airway Management in COVID-19 patients -Consensus Guidelines from the Society for Pediatric Anesthesia's Pediatric Difficult Intubation Collaborative and the Canadian Pediatric Anesthesia Society

Effect of just-in-time simulation training on provider performance and patient outcomes for clinical procedures: A systematic review

Measurement of airborne particle exposure during simulated tracheal intubation using various proposed aerosol containment devices during the COVID-19 pandemic

This article is protected by copyright. All rights reserved